Daiichi Sankyo and Innovent Biologics entered an exclusive agreement for the commercialization of the drug Vanflyta, with Michio Hayashi serving as China President of Daiichi Sankyo.
2 reports, 1 independent
Updated Aug 10
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Daiichi Sankyo and Innovent Biologics entered an exclusive agreement for the commercialization of the drug Vanflyta, with Michio Hayashi serving as China President of Daiichi Sankyo.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Daiichi Sankyo
Japanese pharmaceutical company
-
Innovent Biologics
Chinese Biopharmaceutical Company
Nothing else this week.